Paul Workman is a multidisciplinary cancer research scientist, molecular pharmacologist and chemical biologist who has been responsible for the laboratory discovery and progression into the clinic of many innovative cancer drugs. His specialty is designing personalized cancer medicines that are targeted to precise molecular abnormalities and vulnerabilities – an approach he refers to as ‘drugging the cancer genome’. Paul is particularly well known for the discovery of clinical drug candidates and chemical probes inhibiting protein kinases, PI3 kinases and the molecular chaperone HSP90.